Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:42:28.166Z.
Calculation as of: 2026-10-06T19:42:28.166Z.
Quote observation: 2026-10-06T19:40:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$538.80M
EV/Sales Ratio
2.18x
TTM Avg
5.65x
3Y Avg
62.35x
5Y Avg
62.35x
Market Cap
$535.91M
EV/Sales Ratio
475.28x
TTM Avg
465.17x
3Y Avg
224.57x
5Y Avg
162.02x
Market Cap
$529.60M
EV/Sales Ratio
560.21x
TTM Avg
273.93x
3Y Avg
336.09x
5Y Avg
336.09x
Market Cap
$527.99M
EV/Sales Ratio
5.06x
TTM Avg
4.75x
3Y Avg
15.43x
5Y Avg
15.84x
Market Cap
$554.05M
EV/Sales Ratio
29.64x
TTM Avg
14.16x
3Y Avg
5.32x
5Y Avg
4.09x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $539.25M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $538.80M | 2.18x | 5.65x | 62.35x | 62.35x |
| Shattuck Labs, Inc. (STTK)vs › | $535.91M | 475.28x | 465.17x | 224.57x | 162.02x |
| ProKidney Corp. (PROK)vs › | $529.60M | 560.21x | 273.93x | 336.09x | 336.09x |
| Immix Biopharma, Inc. (IMMX)vs › | $528.79M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $527.99M | 5.06x | 4.75x | 15.43x | 15.84x |
| Nuvectis Pharma, Inc. (NVCT)vs › | $525.16M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $554.05M | 29.64x | 14.16x | 5.32x | 4.09x |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $516.33M | 15774.98x | 12786.98x | 8694.17x | 5938.95x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
